Neurodegenerative Conditions increase with advancing age...

1 in 3 individuals over 80 risk Alzheimer's disease 

1 in 100 individuals over 85 risk Parkinson's disease 

1 in 10,000 risk Huntington's disease

...TBI increases risk of dementia
by as much as two-fold




December 4, 2012:

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Stephen Jacobsen, Ph.D., joined the ALSP Scientific Advisory Board. Dr. Pierschbacher said “We are honored that
Steve has joined our team. His international stellar reputation for innovation in Alzheimer’s disease drug development and his in-depth unders
tanding of the pharmaceutical industry will help accelerate our program to the clinic.” Read More...


October 13-17, 2012: 

Dr. Greg Hook, VP Alzheimer’s Research, ALSP, debuted data on cathepsin B as a target for traumatic brain injury (TBI) and on methods of inhibiting cathepsin B to treat TBI at the Society of Neuroscience meeting in New Orleans, LA, October 13 – 17, 2012.Read More...


September 5, 2012: 

Dr. Michael D. Pierschbacher, CEO, ALSP, announced that Dr. Bernice Wells, MD, MBA, joined the ALSP Board of Directors.  Dr. Pierschbacher said “Bernice is truly an exceptional individual as she has extensive venture capital experience, pharmaceutical industry experience and is a physician.  Her business and technical insight will help insure ALSP succeeds.” Read More...


July 16-18, 2012: 

 Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Vancouver, Canada, July 16 – 18, 2012.  They provided data validating the protease cathepsin B as a key therapeutic target for treating Alzheimer’s disease, and demonstrating the oral efficacy of a cathepsin B inhibitor in an Alzheimer’s disease animal model representative of most Alzheimer’s disease patients. Read More...


May 14-15, 2012:  

The National Institute on Aging’s Alzheimer’s Disease Research Summit was held in Bethesda, MD, at which Health and Human Services Secretary Kathleen Sebelius released the ambitious national plan to fight Alzheimer’s disease called the National Alzheimer’s Project (NAPA), which set forth five goals, including the development of an effective treatment for Alzheimer’s disease by 2025.  The meeting called for public comment on how to achieve those goals.  Dr. Greg Hook, VP Alzheimer’s Research, and Dr. Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, attended and participated in the meeting and provided recommendations to NAPA. Read More...



April 21 - 25, 2012:

 Dr. Greg Hook of ALSP Inc. and his colleagues Dr. Vivian Hook of UCSD and Dr. Mark Kindy of the Medical University of South Carolina, presented at THE AMERICAN SOCIETY FOR MOLECULAR BIOCHEMISTRY AND MOLECULAR BIOLOGY in San Diego, CA. Read More…


To read more about previous ALSP Inc. news and events, please click here.


Focusing on a Future without Neurodegeneration



ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held

company based in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on Alzheimer's disease and traumatic brain injury (TBI). Our approach is to identify key enzymes in the brain, called neuroproteases, that produce biologically active peptides that are thought to cause the condition. We then use those enzymes as targets for screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides to treat the condition.

Since Drs. Katz, von Euler and Axelrod were awarded the Nobel Prize in Physiology or Medicine in 1970 for their discoveries concerning the humoral transmitters in the nerve terminals and the mechanism for their storage, release and inactivation, the process of studying neurotransmitters and the enzymes that produce them have flourished. By using this well-established process, we have identified a family of drugs that is highly effective at reversing the symptoms of Alzheimer's and TBI in animal models of these conditions. We are advancing our lead compound into clinical trials and continuing our search for additional drugs to treat Alzheimer’s and other devastating neurodegenerative diseases.

If my husband has Alzheimers I have Alzheimers, click here to stop it by 2020!

ALSP, Inc. welcomes inquiries from potential investors and others who are united in the cause to put an end to the devastating afflications of the world's aging population.